Study guide
1.3 Dyslipidemia & Thyroid Disorders
DHA Healthcare Professional Licensing Assessment - General Practitioner/Doctor Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Chronic Cardiovascular & Endocrine Disorders
1.1 Hypertension Management in Primary Care 1.2 Type 2 Diabetes Mellitus Management 1.3 Dyslipidemia & Thyroid Disorders
2 Chapter 2: Chronic Respiratory, Renal & Musculoskeletal Disorders
2.1 Asthma & COPD Maintenance 2.2 Chronic Kidney Disease 2.3 Chronic Musculoskeletal & Rheumatological Conditions
3 Chapter 3: Acute & Common Medical Problems
3.1 Common Infections in Primary Care 3.2 Anemia & Hematological Disorders 3.3 Acute Neurological Problems 3.4 Common Gastrointestinal Complaints
4 Chapter 4: Emergency Problems & Resuscitation
4.1 Cardiopulmonary Resuscitation & Shock 4.2 Acute Metabolic & Toxicological Emergencies 4.3 Trauma Assessment & Environmental Emergencies
5 Chapter 5: Common Pediatric Problems
5.1 Acute Pediatric Respiratory Infections 5.2 Febrile Seizures & Childhood Dehydration 5.3 Neonatal Jaundice & Pediatric Developmental Milestones
6 Chapter 6: Women's Health & Obstetric Care
6.1 Antenatal Care, Pre-eclampsia & Gestational Diabetes 6.2 Contraception & Menopause 6.3 Common Gynecological Conditions
7 Chapter 7: Common Surgical Problems
7.1 Acute Abdomen 7.2 Hernias, Hemorrhoids & Testicular Torsion 7.3 Abdominal Aortic Aneurysm & Urological Emergencies
8 Chapter 8: Common Psychiatric Problems
8.1 Mood & Anxiety Disorders 8.2 Psychosis, Delirium & Substance Use 8.3 Suicide Risk Assessment & Crisis Intervention
9 Chapter 9: Common Eye & ENT Problems
9.1 Acute Red Eye, Glaucoma & Uveitis 9.2 Otitis Media, Epistaxis & Vertigo 9.3 Common Upper Respiratory ENT Infections
10 Chapter 10: Common Dermatology Problems
10.1 Acne & Psoriasis 10.2 Eczema, Dermatitis & Skin Infections 10.3 Skin Infestations & Cutaneous Malignancies
11 Chapter 11: Family Medicine Concepts & Health Promotion
11.1 Patient-Centered Care & Continuity 11.2 Immunization & Travel Medicine 11.3 Smoking Cessation & Lifestyle Medicine
12 Chapter 12: Screening & Preventive Medicine
12.1 Cancer Screening 12.2 Cardiovascular & Metabolic Risk Screening
13 Chapter 13: Epidemiology, EBM, Ethics & UAE Regulations
13.1 Basic Epidemiology & Outbreak Measures 13.2 Evidence-Based Medicine & Study Designs 13.3 Professionalism, Ethics & UAE Regulations
1.3 Dyslipidemia & Thyroid Disorders
Key Takeaways Explain This Topic AI
ASCVD 10-year risk scoring guides primary prevention statin choice: moderate-intensity statins are used for intermediate risk (7.5% to <20%), and high-intensity statins for high risk (>=20%).
Established ASCVD represents a mandatory indication for secondary prevention with high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) to achieve >=50% LDL-C reduction.
Gemfibrozil is contraindicated with statins due to a significantly increased risk of rhabdomyolysis; fenofibrate is the preferred fibrate if co-administration is necessary.
Levothyroxine dosing should begin at a low dose (12.5-25 mcg daily) in elderly patients or those with coronary artery disease to avoid precipitating angina or tachyarrhythmias.
Thionamides (Methimazole and PTU) carry risks of life-threatening agranulocytosis, necessitating a complete blood count if the patient presents with a fever or sore throat.
Last updated: July 2026
Dyslipidemia & Thyroid Disorders
Cardiovascular risk reduction and endocrine balance are closely linked in primary care. Managing dyslipidemia through risk-directed statin therapy and diagnosing thyroid dysfunction through standard serological testing are crucial skills for primary care clinicians.
1. Dyslipidemia Management & ASCVD Risk Stratification
Pharmacological management of dyslipidemia focuses on lowering low-density lipoprotein cholesterol (LDL-C) to prevent atherosclerotic cardiovascular disease (ASCVD).
ASCVD Risk Scoring
For primary prevention (patients without established ASCVD), clinical decisions are guided by the 10-Year ASCVD Risk Calculator (using the Pooled Cohort Equations). This tool estimates the risk of a first cardiovascular event (nonfatal MI, coronary heart disease death, or stroke) over the next decade.
Low Risk: < 5%
Borderline Risk: 5% to < 7.5% (consider statin if risk-enhancing factors like family history of premature ASCVD are present)
- Intermediate Risk: 7.5% to < 20% (initiate moderate-intensity statin)
- High Risk: >= 20% (initiate high-intensity statin)
- Primary vs. Secondary Prevention Strategies
Secondary Prevention: Patients with established ASCVD (history of MI, stroke, TIA, stable/unstable angina, coronary revascularization, or peripheral arterial disease) are at extremely high risk. Regardless of baseline lipid levels, these patients must be initiated on a high-intensity statin with a goal of achieving a >= 50% reduction in LDL-C and an absolute target LDL-C < 55 mg/dL or < 70 mg/dL depending on the specific international guideline.
Primary Prevention:
Severe Hypercholesterolemia (LDL-C >= 190 mg/dL): Initiate a high-intensity statin without performing risk scoring.
Diabetes Mellitus (Aged 40–75): Diabetic patients automatically qualify for at least a moderate-intensity statin regardless of their calculated ASCVD risk score. If their 10-year risk is >= 20% or multiple risk factors are present, high-intensity statin therapy is indicated.
General Population (Aged 40–75): Statin initiation is determined by the 10-year risk score (initiate moderate-intensity if risk is 7.5%–20%).
2. Statin Intensity and Safety Profile
Statins (HMG-CoA reductase inhibitors) are classified by their ability to lower LDL-C:
- Intensity Expected LDL-C Reduction Common Regimens
- High-Intensity >= 50% Atorvastatin 40–80 mg; Rosuvastatin 20–40 mg
Moderate-Intensity 30% to < 50% Atorvastatin 10–20 mg; Rosuvastatin 5–10 mg; Simvastatin 20–40 mg; Pravastatin 40–80 mg
- Low-Intensity < 30% Pravastatin 10–20 mg; Lovastatin 20 mg
- Adverse Effects & Drug Interactions
Statin-Associated Muscle Symptoms (SAMS): Ranges from simple myalgias (bilateral, proximal muscle pain/weakness without CK elevation) to myopathy (pain with CK elevation) and rhabdomyolysis (severe pain, creatine kinase [CK] > 10 times the upper limit of normal, brown urine containing myoglobin, and acute renal failure).
Monitoring: Check baseline liver enzymes (ALT) prior to starting a statin. Routine serial monitoring of ALT or CK is not recommended unless the patient becomes symptomatic (e.g., muscle aches, dark urine, or signs of hepatotoxicity like jaundice).
Contraindications: Gemfibrozil must never be co-administered with statins because it inhibits statin glucuronidation, raising statin serum levels and dramatically increasing the risk of rhabdomyolysis. If a fibrate is necessary in combination with a statin, fenofibrate is preferred.
3. Thyroid Disorders: Diagnosis and Interpretation
Evaluation of thyroid function begins with measuring Thyroid Stimulating Hormone (TSH) . If TSH is abnormal, a Free Thyroxine (FT4) level is obtained.
- Condition TSH Level Free T4 (FT4) Level Primary Etiology / Feature
- Primary Hypothyroidism Elevated (High) Decreased (Low) Hashimoto's thyroiditis (Autoimmune)
- Subclinical Hypothyroidism Elevated (High) Normal Often asymptomatic; monitor or treat if TSH > 10
- Secondary (Central) Hypothyroidism Decreased or Normal Decreased (Low) Pituitary or hypothalamic dysfunction
- Primary Hyperthyroidism Decreased (Low) Elevated (High) Graves' disease (Autoimmune TSI)
- Subclinical Hyperthyroidism Decreased (Low) Normal Monitor; risk of atrial fibrillation and osteoporosis
- 4. Management of Hypothyroidism
Pharmacotherapy: Levothyroxine (synthetic T4) is the treatment of choice.
Dosing Guidelines:
Young, Healthy Adults: Full replacement dose of approximately 1.6 mcg/kg/day (based on ideal body weight).
Elderly Patients or Patients with Coronary Artery Disease (CAD): Initiate at a low dose of 25 mcg daily (or 12.5 mcg in frail patients) and titrate slowly. Levothyroxine increases cardiac output and myocardial oxygen demand. Rapid replacement can precipitate angina, myocardial infarction, or tachyarrhythmias (such as atrial fibrillation) in vulnerable patients.
Monitoring: Check TSH 6–8 weeks after initiating therapy or adjusting the dose. Do not check earlier, as it takes several weeks for the pituitary-thyroid feedback loop to stabilize.
- 5. Management of Hyperthyroidism
- Etiologies
Graves' Disease: Autoimmune activation of the TSH receptor. Characterized by a diffuse, symmetric goiter, exophthalmos, and diffuse, homogenous uptake on a Radioactive Iodine Uptake (RAIU) scan.
Toxic Multinodular Goiter & Toxic Adenoma: Autonomously functioning nodules. RAIU shows focal area(s) of increased uptake with suppression of the surrounding gland.
Thyroiditis: Transient inflammation releasing preformed hormone. Characterized by a painful or painless thyroid and very low/absent RAIU because the gland is damaged and not actively synthesizing hormone.
Therapeutic Strategies
Symptom Control: Beta-blockers (e.g., Propranolol) are initiated immediately to control hyperadrenergic symptoms (palpitations, tremors, anxiety, heat intolerance) while awaiting definitive therapy.
Thionamides (Antithyroid Drugs):
Methimazole: First-line for most patients due to once-daily dosing and lower risk of hepatotoxicity. It is, however, teratogenic and contraindicated in the first trimester of pregnancy.
Propylthiouracil (PTU): Preferred in the first trimester of pregnancy (lower teratogenic profile) and in default scenario of thyroid storm (as it blocks the peripheral conversion of T4 to active T3, whereas methimazole does not).
Life-Threatening Adverse Effect: Both thionamides can cause agranulocytosis (severe depletion of white blood cells). Patients must be instructed to immediately stop the drug and obtain a CBC with differential if they develop a fever, sore throat, or other signs of infection. PTU also carries a black-box warning for severe hepatotoxicity.
Definitive Treatment: Radioactive Iodine (RAI) ablation or surgical thyroidectomy (preferred for large goiters, compressive symptoms, or suspected malignancy). Both options typically result in permanent hypothyroidism, requiring lifelong levothyroxine replacement.
Loading diagram...